格隆汇12月2日丨之江生物(688317.SH)公布，截至2025年11月28日，公司通过上海证券交易所交易系统 以集中竞价交易方式累计回购公司股份109.37万股，占公司当前总股本的比例为0.57%，回购成交的最 高价为22.86元/股，最低价为21.52元/股，支付的资金总额为人民币2416.09万元（不含印花税、交易佣 金等交易费用）。 ...

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

证券代码：688317 证券简称：之江生物 公告编号：2025-066 上海之江生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 25 日（星期二）至 12 月 01 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海之江生物科技 股份有限公司（以下简称"公司"）邮箱 info@liferiver.com.cn 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 02 日（星期二）09:00-10:00 举行 2025 年第三季度业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688317 证券简称：之江生物公告编号：2025-065 上海之江生物科技股份有限公司 关于2025年第三次以集中竞价交易方式回购公司股份的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次回购股份符合相关法律法规的规定及公司的回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股 份》等相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进 展情况及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 ■ 一、回购股份的基本情况 2025年10月15日，上海之江生物科技股份有限公司（以下简称"公司"）召开第五届董事会第十六次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金和股票回 购专项贷款资金通过集中竞价交易方式回购公司部分股份，回购的股份拟用于员工持股计划或股权激 励，回购股份价格不超过人民 ...

Group 1 - The core point of the article is that Zhijiang Biotech has announced a share buyback plan, repurchasing approximately 1.01 million shares, which represents 0.53% of its total share capital of about 192 million shares, with a total expenditure of approximately 22.37 million RMB [1] - The share buyback was conducted through the Shanghai Stock Exchange trading system, with the highest transaction price being 22.86 RMB per share and the lowest at 21.52 RMB per share [1] - For the year 2024, Zhijiang Biotech's revenue composition is heavily weighted towards the in vitro diagnostics industry, accounting for 98.25% of total revenue, while other businesses contribute only 1.75% [1] Group 2 - As of the report, Zhijiang Biotech has a market capitalization of 4.1 billion RMB [2]

证券代码：688317 证券简称：之江生物 公告编号：2025-065 上海之江生物科技股份有限公司 关于2025年第三次以集中竞价交易方式回购公司股份 的进展公告 一、回购股份的基本情况 2025 年 10 月 15 日，上海之江生物科技股份有限公司（以下简称"公司"） 召开第五届董事会第十六次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司以自有资金和股票回购专项贷款资金通过集中竞价 交易方式回购公司部分股份，回购的股份拟用于员工持股计划或股权激励，回购 股份价格不超过人民币 37.99 元/股（含），回购资金总额不低于人民币 6,000 万 元（含），不超过人民币 12,000 万元（含），回购期限自公司董事会审议通过本次 回购方案之日起 12 个月内。具体内容详见公司于 2025 年 10 月 17 日在上海证券 交易所网站（www.sse.com.cn）披露的《关于 2025 年第三次以集中竞价交易方式 回购股份方案的公告》（公告编号：2025-055）。 二、回购股份的进展情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容 ...

Core Insights - The company, Zhijiang Biology, has been successfully selling multiple diagnostic products to the EU market over the past two years, leveraging its CE certification obtained from the European Union [2] Group 1 - The company has relied on its CE certification to ensure stable sales of its diagnostic products in the EU [2] - The interaction with investors indicates a positive outlook on the company's market performance in Europe [2]

Core Viewpoint - Zhijiang Biotech (stock code: 688317) has received overwhelming support from shareholders to engage in foreign exchange derivative trading to mitigate currency risk associated with its international business operations [1][2]. Group 1: Shareholder Meeting and Approval - The second extraordinary general meeting of Zhijiang Biotech was attended by 112 shareholders, representing approximately 72.82 million shares, or 37.9% of the total share capital [1]. - The proposal to conduct foreign exchange derivative trading was approved with a high vote of 99.52% [1]. - The company plans to engage in foreign exchange derivatives with a limit of up to $20 million (or equivalent in other currencies) within 12 months of the approval [1]. Group 2: Business Strategy and Rationale - The company aims to hedge against currency fluctuations due to its import and export operations, which often involve foreign currencies like the US dollar [1][2]. - Although current overseas revenue is modest at around 2.3 million yuan, the company is in a critical phase of expanding its international presence, including markets like Japan [2]. - Zhijiang Biotech is also exploring overseas acquisition targets to diversify its business strategy [2]. Group 3: Financial Performance - For the first three quarters of the year, Zhijiang Biotech reported revenue of 90.43 million yuan, a year-on-year decline of 34.27%, with a net loss attributable to shareholders of 29.38 million yuan [3]. - Despite the revenue drop, the company increased its R&D investment, which accounted for 46.51% of revenue, up 18.11 percentage points from the previous year [3]. - The company has effectively managed its inventory levels, which have returned to normal after previous adjustments [4]. Group 4: Innovation and Drug Development - Zhijiang Biotech has signed a strategic cooperation agreement with Sanyou Biotech to enhance drug development automation, aiming to shorten R&D cycles and improve efficiency [5]. - The company is focusing on innovative drug development, particularly in infectious diseases and oncology, with ongoing preclinical studies [6][7]. - The company is leveraging its expertise in materials science and chip technology to develop organoid technology for personalized medicine and drug screening [6]. Group 5: Future Plans and Financial Strategy - The company plans to establish an independent platform for innovative drug development, indicating a strategic shift towards this area [7]. - Zhijiang Biotech is evaluating various projects for investment, with a focus on synergy with its core business [7]. - The company has over 2 billion yuan in cash, which will be strategically utilized for future investments [7].

Group 1 - The company, Zhijiang Biology, reported that as of September 30, 2025, the total number of shareholders is 14,435 [2]